Ani Pharmaceuticals (ANIP) Liabilities and Shareholders Equity (2010 - 2026)

Ani Pharmaceuticals has disclosed Liabilities and Shareholders Equity across 17 years of filings, most recently posting $1.5 billion for Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity rose 11.25% year-over-year to $1.5 billion; the TTM figure through Jun 2026 stood at $5.8 billion (up 10.7% YoY), while the FY2025 annual figure was $1.4 billion, up 12.14% from the prior year.
• Liabilities and Shareholders Equity came in at $1.5 billion for Q2 2026 at Ani Pharmaceuticals, up from $1.4 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.5 billion in Q2 2026 to a low of $739.1 million in Q3 2022.
• Average Liabilities and Shareholders Equity over 5 years is $1.1 billion, with a median of $917.6 million recorded in 2024.
• The largest YoY upside for Liabilities and Shareholders Equity was 60.58% in 2022 against a maximum downside of 1.49% in 2022.
• Over 5 years, Liabilities and Shareholders Equity stood at $760.1 million in 2022, then gained by 18.99% to $904.4 million in 2023, then soared by 42.02% to $1.3 billion in 2024, then advanced by 12.14% to $1.4 billion in 2025, then gained by 3.73% to $1.5 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $1.5 billion in Q2 2026, $1.4 billion in Q1 2026, and $1.4 billion in Q4 2025.